We're a company founded to improve outcomes for patients with cancer.
ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need.
Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia.
Board & Management
The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics.
Leveraging our leadership and experience in oncolytic viral therapies, we are building a body of pre-clinical and manufacturing data with the goal of conducting early-stage clinical trials in 2022.